A. De Jesus Acosta

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

David M. O’Malley, Giovanni M. Bariani, Philippe A. Cassier et al. · Journal of Clinical Oncology · 2022 · 498 citations · Full text

Medicine, Oncology, Gynecologic Oncology +10

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

Michele Maio, Paolo A. Ascierto, L. V. Manzyuk et al. · Annals of Oncology · 2022 · 445 citations · Full text

Life Sciences, Oncology, Immunotherapy +13

dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer

Florencia McAllister, Danielle M. Pineda, Masaya Jimbo et al. · Cancer Biology & Therapy · 2014 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results

David M. O’Malley, Giovanni M. Bariani, Philippe A. Cassier et al. · Gynecologic Oncology · 2025 · 17 citations

Life Sciences, Genetics, Oncology +13

Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study

David M. O’Malley, Giovanni M. Bariani, Philippe A. Cassier et al. · Gynecologic Oncology · 2022 · 15 citations · Full text

Medicine, Oncology, Dna Repair +11